Jim Cramer on Kodiak Sciences: "That's a Pure Spec Stock"

Kodiak Sciences Inc. (NASDAQ:KOD) is one of the stocks that Jim Cramer shared insight on. When a caller asked about the company during the lightning round, Cramer commented:

“Okay, so here’s the problem with it: that’s a pure spec stock, okay. Why do I say, well, it’s a pure spec. It’s a company that like, does not make any money at all and is losing boatloads. If you like it, accept the risk. But otherwise, no go for me.”

Kodiak Sciences Inc. (NASDAQ:KOD) is a clinical-stage biopharmaceutical company developing therapies for retinal diseases, with its lead candidate, tarcocimab tedromer, in late-stage trials for multiple vision-related conditions. The company reported that its net loss for the second quarter of 2025 was $54.3 million, or $1.03 per share, in comparison to a net loss of $45.1 million, or $0.86 per share, in the same quarter of 2024. It ended the second quarter of 2025 with $104.2 million in cash and cash equivalents. Management indicated that current liquidity is expected to support ongoing and expected operational activities into 2026.

While we acknowledge the potential of KOD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.